Suspension of trading

Spexis AG Stock Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - Swiss Exchange 03:36:37 20/03/25 am AEDT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+1.70%-0.74%+18.48%-10.41% 66.74B
-0.08%+3.28%+37.97%+203.98% 53.32B
+1.78%+54.50%+54.50%+54.50% 48.12B
+0.86%-3.25%-56.60%-55.98% 38.25B
-1.01%+0.10%+52.17%-23.84% 29.85B
+1.02%+2.78%+69.33%+89.65% 23.51B
+2.89%-6.49%+62.90%-53.06% 21.45B
+0.12%+4.16%+81.68%+161.81% 16.47B
+1.44%+0.22%+65.12%+126.78% 16.38B
Average +0.97%+0.61%+29.67%+39.42% 34.9B
Weighted average by Cap. +0.99%+1.09%+33.95%+49.86%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B